WO2012097330A3 - Compositions and methods for treating degenerative muscle conditions - Google Patents

Compositions and methods for treating degenerative muscle conditions Download PDF

Info

Publication number
WO2012097330A3
WO2012097330A3 PCT/US2012/021362 US2012021362W WO2012097330A3 WO 2012097330 A3 WO2012097330 A3 WO 2012097330A3 US 2012021362 W US2012021362 W US 2012021362W WO 2012097330 A3 WO2012097330 A3 WO 2012097330A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
subjects suffering
disclosed
degenerative muscle
Prior art date
Application number
PCT/US2012/021362
Other languages
French (fr)
Other versions
WO2012097330A2 (en
Inventor
Nicholas LERONIMAKIS
Hannele RUOHOLA-BAKER
Morayma Reyes
Junlin QI
Mario PANTOJA
Karin Fischer
Original Assignee
University Of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Washington filed Critical University Of Washington
Publication of WO2012097330A2 publication Critical patent/WO2012097330A2/en
Publication of WO2012097330A3 publication Critical patent/WO2012097330A3/en
Priority to US13/941,355 priority Critical patent/US20140051729A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Abstract

Methods and compositions for treating degenerative muscle conditions are disclosed. The compositions disclosed herein include S1P promoting compositions that include an S1P promoting agent. In certain embodiments disclosed herein, the S1P promoting agent is selected from S1P, 1-[5-[(1R,2S,3R)-1,2,3,4-tetrahydroxybutyl]-1H-imidazol-2-yl]-ethanone (THI), biologically active derivatives of THI, and sphingosine analogs. Embodiments of the methods disclosed herein include administering therapeutically effective amounts to subjects suffering from a degenerative muscle condition, such as, for example, subjects suffering from sarcopenia and subjects suffering from muscular dystrophy, including subjects suffering from Duchenne Muscular Dystrophy and Becker Muscular Dystrophy.
PCT/US2012/021362 2011-01-14 2012-01-13 Compositions and methods for treating degenerative muscle conditions WO2012097330A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/941,355 US20140051729A1 (en) 2011-01-14 2013-07-12 Compositions and methods for treating degenerative muscle conditions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161433117P 2011-01-14 2011-01-14
US61/433,117 2011-01-14
US201161548581P 2011-10-18 2011-10-18
US61/548,581 2011-10-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/941,355 Continuation-In-Part US20140051729A1 (en) 2011-01-14 2013-07-12 Compositions and methods for treating degenerative muscle conditions

Publications (2)

Publication Number Publication Date
WO2012097330A2 WO2012097330A2 (en) 2012-07-19
WO2012097330A3 true WO2012097330A3 (en) 2012-11-01

Family

ID=46507699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/021362 WO2012097330A2 (en) 2011-01-14 2012-01-13 Compositions and methods for treating degenerative muscle conditions

Country Status (1)

Country Link
WO (1) WO2012097330A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201900013890A1 (en) * 2019-08-02 2021-02-02 Univ Degli Studi Di Firenze PHARMACEUTICAL COMPOSITION OF S1PR MODULATORS
TW202128675A (en) 2019-12-06 2021-08-01 美商維泰克斯製藥公司 Substituted tetrahydrofurans as modulators of sodium channels
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090030050A1 (en) * 2007-03-01 2009-01-29 Augeri David J Heterocyclic Compounds, Compositions Comprising Them and Methods of Their Use
US20090068180A1 (en) * 2007-09-06 2009-03-12 Tamas Oravecz Compositions and methods for treating immunological and inflammatory diseases and disorders
WO2010010127A1 (en) * 2008-07-23 2010-01-28 Novartis Ag Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
WO2010055028A2 (en) * 2008-11-11 2010-05-20 Novartis Ag Organic compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090030050A1 (en) * 2007-03-01 2009-01-29 Augeri David J Heterocyclic Compounds, Compositions Comprising Them and Methods of Their Use
US20090068180A1 (en) * 2007-09-06 2009-03-12 Tamas Oravecz Compositions and methods for treating immunological and inflammatory diseases and disorders
WO2010010127A1 (en) * 2008-07-23 2010-01-28 Novartis Ag Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
WO2010055028A2 (en) * 2008-11-11 2010-05-20 Novartis Ag Organic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHIARA DONATI ET AL.: "Sphingosine 1-phosphate regulates myogenic differentiation: a major role for S1P2 receptor", THE FASEB JOURNAL, vol. 19, no. 3, 2005, pages 449 - 451, XP008119605, DOI: doi:10.1096/fj.04-1780fje *

Also Published As

Publication number Publication date
WO2012097330A2 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
BR112015007182A2 (en) gdf-8 inhibitors
UA109991C2 (en) CARBAMATE COMPOUNDS, THEIR PREPARATION AND APPLICATION
MX2009012558A (en) Drug combinations for the treatment of duchenne muscular dystrophy.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
WO2013188792A3 (en) Neuroactive steroids, compositions, and uses thereof
EA201491060A1 (en) NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE
BR112015014753A2 (en) compositions, use of a composition, method for combating phytopathogenic fungi and seed
WO2015031564A3 (en) Substituted-1h-benzo[d]imidazole compounds as lysine-specific demethylase 1 (lsd1 ) inhibitors
MX2014000341A (en) Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease.
EA201692506A3 (en) ANTI-FLY VIRUS REPLICATION INHIBITORS
BR112012016797A2 (en) low dynamic intensifier using built-in equalizer compressor
MX2010002392A (en) Improved brimonidine compositions for treating erythema.
MX338554B (en) Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain.
AU2016219643A1 (en) Pharmaceutical combination for the treatment of pain
MX357780B (en) Polycyclic derivatives, preparation method and medical uses thereof.
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
BR112013028095A2 (en) csf-1r inhibitors for the treatment of brain tumors
EA201070477A1 (en) TRANS-CLOMIFEN FOR THE TREATMENT OF METABOLIC SYNDROME
MX2011008910A (en) Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same.
WO2012170918A3 (en) Methods of treatment for retinal diseases
WO2013061004A8 (en) Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
EA201270226A1 (en) VITAMIN D3 AND HIS ANALOGY FOR THE TREATMENT OF ALOPECIA
WO2012050831A3 (en) Combination treatment for dermatological conditions
EA201001747A1 (en) BENZOXASINIC DERIVATIVES, ACTING AS AN AGONIST BETA-2-ADRENOCEPTOR, FOR THE TREATMENT OF RESPIRATORY DISORDERS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12734458

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12734458

Country of ref document: EP

Kind code of ref document: A2